Geron (GERN) Capital Expenditures Growth (3y) (2013 - 2024)
Powered by 
Analysis
Geron (GERN) Capital Expenditures Growth (3y) (2013 - 2024) Analysis & Trends
Peer Set
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Capex Growth (3y) (Qtr) |
|---|---|---|---|---|---|
| 1 | Amgen | 206.44 Bn | 192.45 Bn | 7.24 Bn | 23.70% |
| 2 | Gilead Sciences | 179.97 Bn | 176.79 Bn | 6.22 Bn | 0.24% |
| 3 | Vertex Pharmaceuticals | 130.57 Bn | 122.72 Bn | 2.84 Bn | 23.48% |
| 4 | Regeneron Pharmaceuticals | 81.63 Bn | 73.63 Bn | 3.93 Bn | 63.07% |
| 5 | Argenx Se | 60.34 Bn | 55.16 Bn | 1.37 Bn | - |
| 6 | Moderna | 54.37 Bn | 49.23 Bn | 52.00 Mn | -45.93% |
| 7 | Alnylam Pharmaceuticals | 33.07 Bn | 29.76 Bn | 992.69 Mn | 29.63% |
| 8 | Biogen | 31.84 Bn | 30.55 Bn | 1.96 Bn | -16.79% |
| 9 | Roivant Sciences | 29.49 Bn | 29.49 Bn | 1.16 Mn | - |
| 10 | Geron | 914.60 Mn | 613.75 Mn | - | - |
Historic Data
Download Data
Historic Data
| Date | Value |
|---|---|
| Dec 31, 2024 | 64.52% |
| Jun 30, 2024 | 26.05% |
| Mar 31, 2024 | -39.82% |
| Dec 31, 2023 | 26.61% |
| Sep 30, 2023 | -59.78% |
| Jun 30, 2023 | 170.44% |
| Mar 31, 2023 | -97.39% |
| Dec 31, 2022 | -190.11% |
| Sep 30, 2022 | 165.69% |
| Jun 30, 2022 | -15.94% |
| Mar 31, 2022 | 68.22% |
| Dec 31, 2021 | -45.81% |
| Sep 30, 2021 | -35.21% |
| Jun 30, 2021 | -132.35% |
| Mar 31, 2021 | 253.60% |
| Sep 30, 2020 | 36.29% |
| Dec 31, 2019 | -223.35% |
| Mar 31, 2019 | 289.13% |
| Dec 31, 2018 | -199.37% |
| Mar 31, 2018 | -145.05% |